The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public warning and recall for all batches of MR.7 Super 700000 capsules, citing serious safety concerns over undisclosed pharmaceutical ingredients.
In a notice released on Monday, NAFDAC stated the recall was initiated by the manufacturer, StuffbyNainax LLC, following testing by the U.S. Food and Drug Administration (FDA). The testing revealed the product contains undeclared sildenafil and tadalafil, active pharmaceutical ingredients typically found in prescription medications for erectile dysfunction.
The agency classified the capsules as unapproved drugs. Because sildenafil and tadalafil—both phosphodiesterase type 5 (PDE-5) inhibitors—were not listed on the product label, their safety and efficacy have not been verified. The product, which was marketed online as a dietary supplement for male enhancement, is illegal to sell as a supplement when it contains these prescription substances.
NAFDAC strongly advised the public to cease using or selling the product and to return any remaining capsules to the nearest NAFDAC office. The recall applies to all circulating batches of the product manufactured by StuffbyNainax LLC.
The agency highlighted significant health risks associated with undeclared PDE-5 inhibitors. These substances can dangerously interact with nitrates, commonly prescribed for heart conditions like angina. This interaction can cause a severe, potentially fatal drop in blood pressure. Individuals with diabetes, hypertension, high cholesterol, or heart disease—particularly those taking nitrate-based medications—are at highest risk.
This alert is part of NAFDAC’s ongoing efforts to combat unsafe and falsified medicines in Nigeria. It follows a recent warning about suspected counterfeit Avastin (Bevacizumab) 400 mg vials, a critical cancer medication, which was flagged after authenticity concerns arose at a local hospital.
NAFDAC reiterated its commitment to safeguarding public health through stringent monitoring of drug safety and quality. The agency urged healthcare professionals and consumers to report any suspected counterfeit or substandard medicines, as well as any adverse reactions, through its official reporting channels to support continued vigilance and regulatory action.
